1. Home
  2. People
  3. Vanderlaan, Albert

Albert Vanderlaan

Partner

Boston

Albert Vanderlaan is a partner in Orrick’s Capital Markets Group. He works with public and private companies, SPACs, SPAC sponsors, venture capital firms and investment banks focused on the life sciences and high-growth technology sectors.

Albert is involved in a broad range of corporate legal engagements for high growth technology companies, including IPOs, follow-on public offerings, private and public company securities law compliance matters, public company disclosure obligations, de-SPAC transactions, SPAC IPOs, venture financings and mergers and acquisitions. He also regularly advises public and private companies and their boards of directors on corporate governance issues.

Albert's clients include public and private companies in technology, automotive, Internet related industries, real estate, finance and the life sciences (including, among others, immuno-oncology, gene therapy, restorative cell therapy and medical device companies). He also represents underwriters in initial public offerings, follow-on offerings and PIPE offerings and venture capital firms in a variety of investment transactions.

Albert was named to the Deal’s Top Rising Stars 2021 list, which recognizes top new partners at U.S. law firms who are “doing spectacular work in the field of deal-making and who have continued to progress in their career despite the obstacles put in front of them.”

  • Prior to joining Orrick, Albert was an attorney with Gunderson Dettmer and Cooley.

  • Albert's engagements include:

    • Kineta, Inc. in its $6.0 million registered direct offering in April 2023
    • Kineta, Inc. in its up to $17.5 million at-the-market offering launched in February 2023 
    • COVA Acquisition Corp., a SPAC sponsored by Crescent Cove Advisors and affiliates, in its business combination with ECARX Holdings, Inc. ($3.8 billion), which closed in December 2022 
    • Kineta, Inc., a clinical-stage biotechnology company developing immunotherapies, in its reverse merger with Yumanity Therapeutics, Inc., which closed in December 2022 
    • Local Bounti Corporation in its $23.3 million PIPE offering in October 2022
    • Fisker Inc. in its up to $350 million at-the-market offering launched in May 2022
    • Local Bounti Corporation as corporate and disclosure counsel in its $122.5 million acquisition of Pete's
    • Dave Inc. in its $100 million convertible note financing in March 2022
    • Dave Inc. in its business combination with VPC Impact Acquisition Holdings III, Inc., a SPAC sponsored by Victory Park Capital ($4.0 billion), which closed in January 2022
    • Genesis Growth Tech Acquisition Corp., a special purpose acquisition company targeting companies in Europe, in its upsized $220 million initial public offering in December 2021
    • Local Bounti Corporation in its business combination with Leo Holdings III Corp, a SPAC sponsored by Lion Capital ($1.1 billion), which closed in November 2021
    • Reprise, Inc. in its $62 million Series B financing announced in November 2021
    • Volta Industries, Inc. in its business combination with Tortoise Acquisition Corp. II, a SPAC ($1.4 billion), which closed in August 2021
    • Fisker Inc. in its upsized $600 million 2.5% convertible note offering in August 2021
    • Locus in its $50 million Series C financing in June 2021
    • COVA Acquisition Corp., a special purpose acquisition company targeting companies in Southeast Asia, in its upsized $300 million initial public offering in February 2021
    • Reprise, Inc. in its $17 million Series A financing in February 2021
    • Luminar Technologies, Inc. in its business combination with Gores Metropoulos, Inc., a SPAC sponsored by affiliates of The Gores Group, LLC and Metropoulos & Co. ($3.4 billion), which closed in December 2020
    • Fisker Inc. in its business combination with Spartan Energy Acquisition Corp., a SPAC sponsored by an affiliate of Apollo Global Management, Inc. ($2.9 billion), which closed in October 2020
    • Histogenics Corporation in its reverse merger with Ocugen, Inc.*
    • ARMO BioSciences, Inc. in its acquisition by Eli Lilly for $1.6 billion*
    • Vanda Pharmaceuticals Inc. in its $101 million follow-on public offering*
    • Synchronoss Technologies, Inc. in its sale of Intralinks Holdings, Inc. for $977 million*
    • Partner Therapeutics, Inc. in its acquisition of assets related to Leukine from sanofi-aventis U.S. LLC*
    • Synchronoss Technologies, Inc. in its acquisition of Intralinks Holdings, Inc. for $821 million*
    • REGENXBIO Inc. in its $250 million IPO*
    • Synchronoss Technologies, Inc. in its $230 million offering of 0.75% senior convertible notes*
    • Vitae Pharmaceuticals, Inc. in its acquisition by Allergan for $639 million*

    *Please note: Albert's experience includes that prior to joining Orrick.